Advertisement
News
Advertisement

FDA grants orphan status for Halo's DMD drug candidate

Wed, 01/04/2012 - 10:46am
Mass High Tech: The Journal of New England Technology

Halo Therapeutics LLC, a Newton biotech founded through a unique do-it-yourself drug development process, has won orphan drug designation from the U.S. Food and Drug Administration for HT-100, its treatment for Duchenne muscular dystrophy (DMD).

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading